Filed by Keryx Biopharmaceuticals, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
14a-12
of the Securities Exchange Act of 1934
Subject Corporation:
Keryx Biopharmaceuticals, Inc.
Commission File No.:
000-30929
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection
with Pending Merger with Akebia Therapeutics
Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders to vote
FOR
the Merger
Proposals
Keryx Special Meeting of Stockholders Scheduled for December 11, 2018
BOSTON, Mass. October 30, 2018 Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that it and Akebia Therapeutics, Inc. (NASDAQ:
AKBA) have filed definitive proxy materials with the U.S. Securities and Exchange Commission (SEC) in connection with their respective Special Meetings of Stockholders that have been called to approve the previously announced proposed
merger of Keryx and Akebia. The definitive joint proxy statement is available on the Investor Relations section of Keryxs website, as well as www.sec.gov, and will be mailed to all Keryx common stockholders entitled to vote at the Special
Meeting.
Keryxs Special Meeting of Stockholders is scheduled to take place on December 11, 2018 at the offices of Goodwin Procter LLP, 100
Northern Avenue, Boston, Massachusetts 02210 at 11:00 a.m. Eastern Time. All Keryx common stockholders of record as of the close of business on October 22, 2018 will be entitled to vote their shares either in person or by proxy at the Special
Meeting.
The Keryx Board is enthusiastic and unanimous in its support of the Akebia merger and believes this transaction maximizes value for Keryx
stockholders, said Michael W. Rogers, Chairman of the Keryx Board of Directors. We encourage our stockholders to vote their shares in favor of this transformational merger, which creates a renal-focused company with a commitment to
developing and delivering innovative therapeutic products.
The Keryx Board unanimously recommends that Keryx stockholders vote
FOR
the merger-related proposals included in the definitive joint proxy statement.
If you have any questions, require assistance with voting your proxy
card, or need additional copies of the proxy materials, please contact:
Georgeson
1290 Avenue of the Americas, 9th Floor
New York, NY 10104
Toll-Free: (888)
680-1525
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals,
Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team works with passion to advance the
care of people with this complex disease. This dedication has resulted in two
FDA-approved
indications for Keryxs first medicine, Auryxia (ferric citrate) tablets. For more information about Keryx,
please visit www.keryx.com.
1